81 FR 22995 - National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Closed Meetings

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

Federal Register Volume 81, Issue 75 (April 19, 2016)

Page Range		22995-22996
FR Document		2016-08995

Federal Register, Volume 81 Issue 75 (Tuesday, April 19, 2016)

[Federal Register Volume 81, Number 75 (Tuesday, April 19, 2016)]
[Notices]
[Pages 22995-22996]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2016-08995]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute of Diabetes and Digestive and Kidney Diseases; 
Notice of Closed Meetings

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. App.), notice is hereby given of the following 
meetings.
    The meetings will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute of Diabetes and Digestive 
and Kidney Diseases Special Emphasis Panel; PAR-13-228: Biomarkers 
for Diabetes and Kidney Diseases using Biosamples from the NIDDK 
Repository (R01).
    Date: June 1, 2016.
    Time: 11:00 a.m. to 1:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, Two Democracy Plaza, 6707 
Democracy Boulevard, Bethesda, MD 20892 (Telephone Conference Call).
    Contaact Person: Najma Begum, Ph.D., Scientific Review Officer, 
Review Branch, DEA, NIDDK, National Institutes of Health, ROOM 7349, 
6707 Democracy Boulevard, Bethesda, MD 20892-5452, (301) 594-8894, 
[email protected].

    Name of Committee: National Institute of Diabetes and Digestive 
and Kidney Diseases Special Emphasis Panel; NIDDK-KUH Fellowship 
Review.
    Date: June 3, 2016.
    Time: 8:00 a.m. to 9:00 a.m.
    Agenda: To review and evaluate grant applications.
    Place: Melrose Hotel, 2430 Pennsylvania Ave. NW., Washington, DC 
20037.
    Contact Person: Xiaodu Guo, MD, Ph.D., Scientific Review 
Officer, Review Branch, DEA, NIDDK, National Institutes of Health, 
Room 7023, 6707 Democracy Boulevard,

[[Page 22996]]

Bethesda, MD 20892-5452, (301) 594-4719, [email protected].

    Name of Committee: National Institute of Diabetes and Digestive 
and Kidney Diseases Special Emphasis Panel; NIDDK Member Conflict 
SEP.
    Date: June 3, 2016.
    Time: 9:00 a.m. to 5:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Melrose Hotel, 2430 Pennsylvania Ave. NW., Washington, DC 
20037.
    Contact Person: Xiaodu Guo, MD, Ph.D., Scientific Review 
Officer, Review Branch, DEA, NIDDK, National Institutes of Health, 
Room 7023, 6707 Democracy Boulevard, Bethesda, MD 20892-5452, (301) 
594-4719, [email protected].

    Name of Committee: National Institute of Diabetes and Digestive 
and Kidney Diseases Special Emphasis Panel; RFA-DK-15-027: Human 
Pancreas Procurement and Analysis Program (HPPAP) (UC4].
    Date: June 6, 2016.
    Time: 10:00 a.m. to 12:30 p.m.
    Agenda: To review and evaluate cooperative agreement 
applications.
    Place: National Institutes of Health, Two Democracy Plaza, 6707 
Democracy Boulevard, Bethesda, MD 20892 (Telephone Conference Call).
    Contact Person: Najma Begum, Ph.D., Scientific Review Officer, 
Review Branch, DEA, NIDDK, National Institutes of Health, Room 7349, 
6707 Democracy Boulevard, BETHESDA, MD 20892-5452, (301) 594-8894, 
[email protected].

    Name of Committee: National Institute of Diabetes and Digestive 
and Kidney Diseases Special Emphasis Panel; RFA DK-15-025: 
Mechanisms Underlying the Contribution of Type 1 Diabetes Risk-
Associated Variants (DP3).
    Date: June 23, 2016.
    Time: 10:00 a.m. to 3:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, Two Democracy Plaza, 6707 
Democracy Boulevard, Bethesda, MD 20892 (Telephone Conference Call).
    Contact Person: Najma Begum, Ph.D., Scientific Review Officer, 
Review Branch, DEA, NIDDK, National Institutes of Health, Room 7349, 
6707 Democracy Boulevard, Bethesda, MD 20892-5452, (301) 594-8894, 
[email protected].

    Name of Committee: National Institute of Diabetes and Digestive 
and Kidney Diseases Special Emphasis Panel; George M. O'Brien 
Urology Cooperative Research Centers Program (U54).
    Date: July 12, 2016.
    Time: 8:00 a.m. to 7:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Residence Inn Capital View, 2850 South Potomac Avenue, 
Arlington, VA 22202.
    Contact Person: Jason D. Hoffert, Ph.D., Scientific Review 
Officer, Review Branch, DEA, NIDDK, National Institutes of Health, 
Room 7343, 6707 Democracy Boulevard, Bethesda, MD 20817, 301-496-
9010, [email protected].

(Catalogue of Federal Domestic Assistance Program Nos. 93.847, 
Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive 
Diseases and Nutrition Research; 93.849, Kidney Diseases, Urology 
and Hematology Research, National Institutes of Health, HHS)


    Dated: April 13, 2016.
David Clary,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2016-08995 Filed 4-18-16; 8:45 am]
 BILLING CODE 4140-01-P

Federal Register / Vol. 81, No. 75 / Tuesday, April 19, 2016 / Notices 22995

Dated: April 8, 2016. Jerusalem, Israel. The patent rights in under the Freedom of Information Act,
Elizabeth A. Fowler, these inventions have been assigned to 5 U.S.C. 552.
Deputy Director for Management Operations the United States of America. This Dated: April 13, 2016.
Indian Health Service. license may be worldwide. The field of Anna Amar,
[FR Doc. 2016–09012 Filed 4–18–16; 8:45 am] use may be limited to the use of the
Acting Deputy Director, Technology
BILLING CODE 4165–16–P Licensed Patent Rights to ‘‘develop the Advancement Office, National Institute of
CB1/iNOS series of compounds as a Diabetes and Digestive and Kidney Diseases,
therapeutic to treat systemic sclerosis, National Institutes of Health.
DEPARTMENT OF HEALTH AND scleroderma, and other skin fibrotic [FR Doc. 2016–08985 Filed 4–18–16; 8:45 am]
HUMAN SERVICES diseases.’’ BILLING CODE 4140–01–P

National Institutes of Health DATES: Only written comments and/or
applications for a license which are
Prospective Grant of Exclusive received by the Technology DEPARTMENT OF HEALTH AND
License: Development of the CB1/iNOS Advancement Office, The National HUMAN SERVICES
Series of Compounds as a Therapeutic Institute of Diabetes and Digestive and
National Institutes of Health
To Treat System Sclerosis, Kidney Diseases on or before May 4,
Scleroderma, and Other Skin Fibrotic 2016 will be considered. National Institute of Diabetes and
Diseases in Humans ADDRESSES: Requests for copies of the Digestive and Kidney Diseases; Notice
AGENCY: National Institutes of Diabetes patent application, patents, inquiries, of Closed Meetings
and Digestive and Kidney Diseases, comments, and other materials relating
to the contemplated exclusive license Pursuant to section 10(d) of the
Public Health Service, PHS, National Federal Advisory Committee Act, as
Institutes of Health. should be directed to: Betty Tong, Ph.D.,
Sr. Licensing and Patenting Manager, amended (5 U.S.C. App.), notice is
ACTION: Notice. hereby given of the following meetings.
Technology Advancement Office, The
The meetings will be closed to the
SUMMARY: This notice, in accordance National Institute of Diabetes and
public in accordance with the
with 35 U.S.C. 209(c)(1) and 37 CFR Digestive and Kidney Diseases, 12A
provisions set forth in sections
part 404.7, that the National Institutes of South Drive, Bethesda, MD 20892,
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
Health, Department of Health and Email: betty.tong@nih.gov. A signed
as amended. The grant applications and
Human Services, is contemplating the confidentiality non-disclosure
the discussions could disclose
grant of an exclusive patent license to agreement will be required to receive
confidential trade secrets or commercial
practice the following inventions copies of any patent applications that
property such as patentable material,
embodied in the following patent have not been published by the United
and personal information concerning
applications, entitled ‘‘CB1 receptor States Patent and Trademark Office or
individuals associated with the grant
mediating compounds’’: the World Intellectual Property
applications, the disclosure of which
Organization.
1. U.S. Provisional Patent Application No.: would constitute a clearly unwarranted
61/991,333, HHS Ref. No.: E–140–2014/ SUPPLEMENTARY INFORMATION: This invasion of personal privacy.
0–US–01, Filed: May 09, 2014 technology, and its corresponding
2. PCT Application No.: PCT/US2015/ Name of Committee: National Institute of
patent applications, is directed to Diabetes and Digestive and Kidney Diseases
029946, HHS Ref. No.: E–140–2014/0–
methods of treating fibrosis, obesity and Special Emphasis Panel; PAR–13–228:
PCT–02, Filed: May 08, 2015
3. U.S. Provisional Patent Application No.: associated diseases such as type 2 Biomarkers for Diabetes and Kidney Diseases
61/725,949, HHS Ref. No.: E–282 –2012/ diabetes by administering an agent that using Biosamples from the NIDDK Repository
0–US–01, Filed: November 13, 2012 reduces appetite, body weight, hepatic (R01).
4. PCT Application No.: PCT/US2013/ steatosis, and insulin resistance. This Date: June 1, 2016.
Time: 11:00 a.m. to 1:00 p.m.
069686, HHS Ref. No.: E–282 –2012/0– technology may be useful as a means for
PCT–02, Filed: November 12, 2013 Agenda: To review and evaluate grant
treating various fibrotic diseases and applications.
5. U.S. Patent Application No.: 14/442,383, metabolic syndromes without serious
HHS Ref. No.: E–282–2012/0–US–03, Place: National Institutes of Health, Two
adverse neuropsychiatric side effects. Democracy Plaza, 6707 Democracy
Filed: May 12, 2015
6. Canadian Patent Application No.: 2889697,
The prospective exclusive license will Boulevard, Bethesda, MD 20892 (Telephone
be royalty bearing and will comply with Conference Call).
HHS Ref. No.: E–282–2012/0–CA–04,
the terms and conditions of 35 U.S.C. Contaact Person: Najma Begum, Ph.D.,
Filed: April 27, 2015
209 and 37 CFR 404.7. The prospective Scientific Review Officer, Review Branch,
7. European Patent Application No.:
DEA, NIDDK, National Institutes of Health,
13802153.0, HHS Ref. No.: E–282–2012/ exclusive license may be granted unless
ROOM 7349, 6707 Democracy Boulevard,
0–EP–05, Filed: June 01, 2015 within fifteen (15) days from the date of Bethesda, MD 20892–5452, (301) 594–8894,
8. Indian Patent Application No.: 3733/ this published notice, the Technology begumn@niddk.nih.gov.
DELNP/2015, HHS Ref. No.: E–282– Advancement Office receives written
2012/0–IN–06, Filed: May 01, 2015 Name of Committee: National Institute of
evidence and argument that establishes Diabetes and Digestive and Kidney Diseases
9. Japanese Patent Application No.: 2015–
542015, HHS Ref. No.: E–282–2012/0–
that the grant of the license would not Special Emphasis Panel; NIDDK–KUH
JP–07, Filed: May 11, 2015 be consistent with the requirements of Fellowship Review.
10. Chinese Patent Application No.: 35 U.S.C. 209 and 37 CFR 404.7. Date: June 3, 2016.
Time: 8:00 a.m. to 9:00 a.m.
mstockstill on DSK4VPTVN1PROD with NOTICES

201380069389.9, HHS Ref. No.: E–282– Properly filed competing applications
2012/0–CN–08, Filed: July 3, 2015 for a license in response to this notice Agenda: To review and evaluate grant
11. US Provisional Application No.: 62/ applications.
will be treated as objections to the
171,179, HHS Ref. No.: E–282–2012/1– Place: Melrose Hotel, 2430 Pennsylvania
contemplated license. Comments and Ave. NW., Washington, DC 20037.
US–01, Filed: June 04, 2015 objections submitted in response to this Contact Person: Xiaodu Guo, MD, Ph.D.,
to Vital Spark Inc., (‘‘Vital Spark’’), a notice will not be made available for Scientific Review Officer, Review Branch,
company incorporated under the laws of public inspection and, to the extent DEA, NIDDK, National Institutes of Health,
Delaware and having an office in permitted by law, will not be released Room 7023, 6707 Democracy Boulevard,

VerDate Sep<11>2014 18:02 Apr 18, 2016 Jkt 238001 PO 00000 Frm 00032 Fmt 4703 Sfmt 4703 E:\FR\FM\19APN1.SGM 19APN1

22996 Federal Register / Vol. 81, No. 75 / Tuesday, April 19, 2016 / Notices

Bethesda, MD 20892–5452, (301) 594–4719, (Catalogue of Federal Domestic Assistance campus. Visitors will be asked to show one
guox@extra.niddk.nih.gov. Program Nos. 93.847, Diabetes, form of identification (for example, a
Name of Committee: National Institute of Endocrinology and Metabolic Research; government-issued photo ID, driver’s license,
Diabetes and Digestive and Kidney Diseases 93.848, Digestive Diseases and Nutrition or passport) and to state the purpose of their
Special Emphasis Panel; NIDDK Member Research; 93.849, Kidney Diseases, Urology visit.
Conflict SEP. and Hematology Research, National Institutes Information is also available on the
Date: June 3, 2016. of Health, HHS) Institute’s/Center’s home page: http://
Time: 9:00 a.m. to 5:00 p.m. deainfo.nci.nih.gov/advisory/ctac/ctac.htm,
Agenda: To review and evaluate grant Dated: April 13, 2016. where an agenda and any additional
applications. David Clary, information for the meeting will be posted
Place: Melrose Hotel, 2430 Pennsylvania Program Analyst, Office of Federal Advisory when available.
Ave. NW., Washington, DC 20037. Committee Policy. (Catalogue of Federal Domestic Assistance
Contact Person: Xiaodu Guo, MD, Ph.D., [FR Doc. 2016–08995 Filed 4–18–16; 8:45 am] Program Nos. 93.392, Cancer Construction;
Scientific Review Officer, Review Branch, 93.393, Cancer Cause and Prevention
BILLING CODE 4140–01–P
DEA, NIDDK, National Institutes of Health, Research; 93.394, Cancer Detection and
Room 7023, 6707 Democracy Boulevard, Diagnosis Research; 93.395, Cancer
Bethesda, MD 20892–5452, (301) 594–4719, Treatment Research; 93.396, Cancer Biology
guox@extra.niddk.nih.gov. DEPARTMENT OF HEALTH AND Research; 93.397, Cancer Centers Support;
HUMAN SERVICES 93.398, Cancer Research Manpower; 93.399,
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases Cancer Control, National Institutes of Health,
National Institutes of Health HHS)
Special Emphasis Panel; RFA–DK–15–027:
Human Pancreas Procurement and Analysis National Cancer Institute; Notice of Dated: April 13, 2016.
Program (HPPAP) (UC4].
Open Meeting Melanie J. Gray,
Date: June 6, 2016.
Time: 10:00 a.m. to 12:30 p.m. Program Analyst, Office of Federal Advisory
Pursuant to section 10(a) of the Committee Policy.
Agenda: To review and evaluate Federal Advisory Committee Act, as
cooperative agreement applications. amended (5 U.S.C. App.), notice is
[FR Doc. 2016–08949 Filed 4–18–16; 8:45 am]
Place: National Institutes of Health, Two BILLING CODE 4140–01–P
Democracy Plaza, 6707 Democracy
hereby given of a meeting of the
Boulevard, Bethesda, MD 20892 (Telephone National Cancer Institute Clinical Trials
Conference Call). and Translational Research Advisory
DEPARTMENT OF HEALTH AND
Contact Person: Najma Begum, Ph.D., Committee.
The meeting will be open to the HUMAN SERVICES
Scientific Review Officer, Review Branch,
DEA, NIDDK, National Institutes of Health, public, with attendance limited to space National Institutes of Health
Room 7349, 6707 Democracy Boulevard, available. Individuals who plan to
BETHESDA, MD 20892–5452, (301) 594– attend and need special assistance, such National Institute of Diabetes and
8894, begumn@niddk.nih.gov. as sign language interpretation or other Digestive and Kidney Diseases Notice
Name of Committee: National Institute of reasonable accommodations, should of Closed Meeting
Diabetes and Digestive and Kidney Diseases notify the Contact Person listed below
Special Emphasis Panel; RFA DK–15–025: Pursuant to section 10(d) of the
in advance of the meeting. The meeting
Mechanisms Underlying the Contribution of Federal Advisory Committee Act, as
Type 1 Diabetes Risk-Associated Variants will also be videocast and can be
accessed from the NIH Videocasting and amended (5 U.S.C. App.), notice is
(DP3). hereby given of the following meeting.
Date: June 23, 2016. Podcasting Web site (http://
videocast.nih.gov/). The meeting will be closed to the
Time: 10:00 a.m. to 3:00 p.m.
Agenda: To review and evaluate grant public in accordance with the
Name of Committee: National Cancer provisions set forth in sections
applications. Institute Clinical Trials and Translational
Place: National Institutes of Health, Two 552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
Research Advisory Committee.
Democracy Plaza, 6707 Democracy Date: July 13, 2016. as amended. The grant applications and
Boulevard, Bethesda, MD 20892 (Telephone Time: 8:00 a.m. to 4:00 p.m. the discussions could disclose
Conference Call). Agenda: Strategic Discussion of NCI’s confidential trade secrets or commercial
Contact Person: Najma Begum, Ph.D., Clinical and Translational Research property such as patentable material,
Scientific Review Officer, Review Branch, Programs. and personal information concerning
DEA, NIDDK, National Institutes of Health, Place: National Institutes of Health, individuals associated with the grant
Room 7349, 6707 Democracy Boulevard, Building 31, C–Wing, 6th Floor, Room 9 and
Bethesda, MD 20892–5452, (301) 594–8894, applications, the disclosure of which
10, 31 Center Drive, Bethesda, MD 20892.
begumn@niddk.nih.gov. would constitute a clearly unwarranted
Contact Person: Sheila A. Prindiville, MD,
Name of Committee: National Institute of MPH Director, Coordinating Center for invasion of personal privacy.
Diabetes and Digestive and Kidney Diseases Clinical Trials, National Institutes of Health, Name of Committee: National Institute of
Special Emphasis Panel; George M. O’Brien National Cancer Institute, 9609 Medical Diabetes and Digestive and Kidney Diseases
Urology Cooperative Research Centers Center Drive, Room 6W136, Rockville, MD Special Emphasis Panel; NEW NIDDK PARs
Program (U54). 20850, 240–276–6173, prindivs@ on Pragmatic Research and Natural
Date: July 12, 2016. mail.nih.gov. Experiments.
Time: 8:00 a.m. to 7:00 p.m. Any interested person may file written Date: May 13, 2016.
Agenda: To review and evaluate grant comments with the committee by forwarding Time: 10:00 a.m. to 5:00 p.m.
applications. the statement to the Contact Person listed on Agenda: To review and evaluate grant
Place: Residence Inn Capital View, 2850 applications.
mstockstill on DSK4VPTVN1PROD with NOTICES

this notice. The statement should include the
South Potomac Avenue, Arlington, VA name, address, telephone number and when Place: National Institutes of Health, Two
22202. applicable, the business or professional Democracy Plaza, 6707 Democracy
Contact Person: Jason D. Hoffert, Ph.D., affiliation of the interested person. Boulevard, Bethesda, MD 20892 (Telephone
Scientific Review Officer, Review Branch, In the interest of security, NIH has Conference Call).
DEA, NIDDK, National Institutes of Health, instituted stringent procedures for entrance Contact Person: Michele L. Barnard, Ph.D.,
Room 7343, 6707 Democracy Boulevard, onto the NIH campus. All visitor vehicles, Scientific Review Officer, Review Branch,
Bethesda, MD 20817, 301–496–9010, including taxicabs, hotel, and airport shuttles DEA, NIDDK, National Institutes of Health,
hoffertj@niddk.nih.gov. will be inspected before being allowed on Room 7353, 6707 Democracy Boulevard,

VerDate Sep<11>2014 18:02 Apr 18, 2016 Jkt 238001 PO 00000 Frm 00033 Fmt 4703 Sfmt 4703 E:\FR\FM\19APN1.SGM 19APN1

Document Created: 2016-04-19 00:15:52
Document Modified: 2016-04-19 00:15:52

Category		Regulatory Information
Collection		Federal Register
sudoc Class		AE 2.7: GS 4.107: AE 2.106:
Publisher		Office of the Federal Register, National Archives and Records Administration
Section		Notices
Dates		June 1, 2016.
FR Citation		81 FR 22995

81 FR 22995 - National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Closed Meetings

DEPARTMENT OF HEALTH AND HUMAN SERVICESNational Institutes of Health

Federal Register Volume 81, Issue 75 (April 19, 2016)

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health